Upfront ALK and VEGFR inhibition re-sensitized ALK-TKI-resistant ALK-positive NSCLC cell lines. Lorlatinib plus bevacizumab achieved disease regression. The gene discussed is KDR; the disease is non-small cell lung carcinoma.